Renal Effects of Melatonin Trial in Chronic Kidney Disease

Renal Function in Chronic Kidney Disease and the Effect of Exogenous Melatonin Administration (REM TRIAL)

This will be a prospective, double blinded, randomized, controlled pilot study to determine if there is any correlation between melatonin administration and proteinuria.

Investigators plan to enroll up to 100 eligible participants in this pilot trial with 50 participants randomized to receive melatonin and 50 patients randomized to receive a placebo. Participants will be randomized on a rolling basis; meaning, once participants agree to enroll in the study, the participant will be placed randomly into either group.

Inclusion Criteria:

• Are between ages 18 and up with chronic kidney disease (CKD) I-III (stage 3 kidney disease, kidney dysfunction)
• Random urine microalbumin of 30 mcg or greater (protein in the urine)
• Have ability to complete a sleep survey
• Currently not on melatonin therapy.

Exclusion Criteria:

• End Stage Renal Disease
• CKD Stage IV (stage 4 with severe kidney dysfunction)
• Severe liver disease
• Chronic dialysis therapy